Related Experiment Video
Updated: Jul 13, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide
Abraham B Schwarzberg1, Elizabeth H Stover, Tanya Sengupta
1Harvard Medical School, Boston, Massachusetts, USA. aschwarzberg@partners.org
Abstract:
Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia. We evaluated the incidence of lymphopenia and opportunistic infections during treatment and up to 12 months following treatment discontinuation in a cohort of 39 patients receiving temozolomide for advanced neuroendocrine tumors. The incidence of Grade 3-4 lymphopenia was 46 percent after 4 months of therapy and remained at 30 percent or greater for 12 months following treatment discontinuation. The overall incidence of opportunistic infections was 10 percent, while among patients receiving therapy for > or =7 months, the incidence was 20 percent. Prophylaxis for Pneumocystis jiroveci pneumonia and varicella-zoster, as well as cytomegalovirus monitoring, should be considered in patients receiving temozolomide-based treatment.
Related Concept Videos
Cryptococcal Meningitis
Tumor Immunotherapy
Treatment Resistent Cancers
Treatment Resistant Cancers